1.Efficacy of Oral Etidronate for Skeletal Diseases in Japan.
Jun IWAMOTO ; Tsuyoshi TAKEDA ; Yoshihiro SATO
Yonsei Medical Journal 2005;46(3):313-320
Etidronate is an oral bisphosphonate compound that is known to reduce bone resorption through the inhibition of osteoclastic activity. The efficacy of etidronate for involutional (postmenopausal and senile) and glucocorticoid-induced osteoporosis, as well as that for other skeletal diseases, was reviewed in Japanese patients. Cyclical etidronate treatment (200 mg or 400mg/day for 2 weeks about every 3 months) increases the lumbar bone mineral density (BMD) in patients with involutional osteoporosis and prevents incident vertebral fractures in patients with glucocorticoid-induced osteoporosis. The losses of the lumbar BMD in patients with liver cirrhosis and the metacarpal BMD in hemiplegic patients after stroke are prevented, and the lumbar BMD is possibly increased, preventing fragile fractures in adult patients with osteogenesis imperfecta type I. Furthermore, proximal bone resorption around the femoral stem is reduced and some complications may be prevented in patients who undergo cementless total hip arthroplasty. Oral etidronate treatment may also help to transiently relieve metastatic cancer bone pain followed by a decrease in abnormally raised bone resorption in patients with painful bone metastases from primary cancer sites, such as the lung, breast and prostate. Thus, oral etidronate treatment is suggested to be efficacious for osteoporosis, as well as other skeletal diseases associated with increased bone resorption, in Japanese patients. Randomized controlled trials needed to be conducted on a large number of patients to confirm these effects.
Administration, Oral
;
Bone Diseases/*drug therapy
;
Etidronic Acid/*administration & dosage
;
Humans
;
Japan
2.Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report.
Jeong Keun LEE ; Kyung Wook KIM ; Jin Young CHOI ; Seong Yong MOON ; Su Gwan KIM ; Chul Hwan KIM ; Hyeon Min KIM ; Yong Dae KWON ; Yong Deok KIM ; Dong Keun LEE ; Seung Ki MIN ; In Sook PARK ; Young Wook PARK ; Min Suk KOOK ; Hong Ju PARK ; Jin A BAEK ; Jun Woo PARK ; Tae Geon KWON
Journal of the Korean Association of Oral and Maxillofacial Surgeons 2013;39(1):9-13
OBJECTIVES: Bisphosphonates (BP) are widely used in medicine for inhibiting bone resorption; however bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a major side effect of BP. To date, there have been no specific reports on the incidence of BRONJ among Koreans. This study investigated the preliminary results from a nationwide survey of BRONJ in the Departments of Oral and Maxillofacial Surgery (OMFS) at individual training hospitals. MATERIALS AND METHODS: A total of 15 OMFS departments (10 from dental schools, 4 from medical schools, and 1 from a dental hospital) participated in a multi-centric survey. This study assessed every BRONJ case diagnosed between January 2010 and December 2010. The patient age and BP type were evaluated. RESULTS: A total of 254 BRONJ cases were collected. The majority of BRONJ cases were associated with oral BP therapy, while 21.8% of the cases were associated with intravenous administration. Alendronate was the drug most frequently related to BRONJ (59.2% of cases), followed by risedronate (14.3%) and zolendronate (17.0%). The average age of BRONJ patients was 70.0+/-10.1 years, with a range of 38-88 years of age. With the number of BP patients in Korea reported to be around 600,000 in 2008, the estimated incidence of BRONJ is at least 0.04% or 1 per 2,300 BP patients. CONCLUSION: The results suggest that the estimated incidence of BRONJ in Korea is higher than the incidence of other countries. Future prospective studies should be carried out to investigate the exact epidemiological characteristics of BRONJ in Korea.
Administration, Intravenous
;
Alendronate
;
Bisphosphonate-Associated Osteonecrosis of the Jaw
;
Data Collection
;
Diphosphonates
;
Etidronic Acid
;
Humans
;
Incidence
;
Jaw
;
Korea
;
Osteonecrosis
;
Schools, Dental
;
Schools, Medical
;
Surgery, Oral
;
Risedronate Sodium
3.Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report.
Jeong Keun LEE ; Kyung Wook KIM ; Jin Young CHOI ; Seong Yong MOON ; Su Gwan KIM ; Chul Hwan KIM ; Hyeon Min KIM ; Yong Dae KWON ; Yong Deok KIM ; Dong Keun LEE ; Seung Ki MIN ; In Sook PARK ; Young Wook PARK ; Min Suk KOOK ; Hong Ju PARK ; Jin A BAEK ; Jun Woo PARK ; Tae Geon KWON
Journal of the Korean Association of Oral and Maxillofacial Surgeons 2013;39(1):9-13
OBJECTIVES: Bisphosphonates (BP) are widely used in medicine for inhibiting bone resorption; however bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a major side effect of BP. To date, there have been no specific reports on the incidence of BRONJ among Koreans. This study investigated the preliminary results from a nationwide survey of BRONJ in the Departments of Oral and Maxillofacial Surgery (OMFS) at individual training hospitals. MATERIALS AND METHODS: A total of 15 OMFS departments (10 from dental schools, 4 from medical schools, and 1 from a dental hospital) participated in a multi-centric survey. This study assessed every BRONJ case diagnosed between January 2010 and December 2010. The patient age and BP type were evaluated. RESULTS: A total of 254 BRONJ cases were collected. The majority of BRONJ cases were associated with oral BP therapy, while 21.8% of the cases were associated with intravenous administration. Alendronate was the drug most frequently related to BRONJ (59.2% of cases), followed by risedronate (14.3%) and zolendronate (17.0%). The average age of BRONJ patients was 70.0+/-10.1 years, with a range of 38-88 years of age. With the number of BP patients in Korea reported to be around 600,000 in 2008, the estimated incidence of BRONJ is at least 0.04% or 1 per 2,300 BP patients. CONCLUSION: The results suggest that the estimated incidence of BRONJ in Korea is higher than the incidence of other countries. Future prospective studies should be carried out to investigate the exact epidemiological characteristics of BRONJ in Korea.
Administration, Intravenous
;
Alendronate
;
Bisphosphonate-Associated Osteonecrosis of the Jaw
;
Data Collection
;
Diphosphonates
;
Etidronic Acid
;
Humans
;
Incidence
;
Jaw
;
Korea
;
Osteonecrosis
;
Schools, Dental
;
Schools, Medical
;
Surgery, Oral
;
Risedronate Sodium